$4.20+0.07 (+1.69%)
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States.
Purple Biotech Ltd in the Healthcare sector is trading at $4.20. The stock is currently near its 52-week low of $3.60, remaining 52.4% below its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why PPBT maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that bl...